ReviewTrends in molecular medicine2021
CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects.
Review in Trends in molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Exploring the Risk Factors of Rosacea Exacerbation Associated with COVID-19 Infection or Vaccination: A Cross-sectional Study.Acta dermato-venereologica · 2025Article
- SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway-targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials.Frontiers in neurology · 2025Article
- CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients.Journal of virology · 2024Article
- Calcitonin Gene-Related Peptide Systemic Effects: Embracing the Complexity of Its Biological Roles-A Narrative Review.International journal of molecular sciences · 2023Review
- Calcitonin Gene-Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder.JAMA network open · 2023Article
- CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond.Physiological reviews · 2023Review
- A Pharmacological Review of Calcitonin Gene-Related Peptide Biologics and Future Use for Chronic Pain.Cureus · 2023Review
- Serum Calcitonin Gene-Related Peptide α and β Levels are Increased in COVID-19 Inpatients.Archives of medical research · 2023Article
- COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report.Internal and emergency medicine · 2021Article
- Response to Letter to the Editor from Abobaker and Darrat: "Circulating levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients".Journal of the Endocrine Society · 2021Article
- Letter to the Editor From Abobaker and Darrat: "Circulating Levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients".Journal of the Endocrine Society · 2021Article
- Circulating Levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients.Journal of the Endocrine Society · 2021Article
- CGRP Regulates Nucleus Pulposus Cell Apoptosis and Inflammation via the MAPK/NF-Oxidative medicine and cellular longevity · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antagonizing CGRP in COVID-19. Awareness regarding potential cardiopulmonary adverse effects may enable their early detection and prevent illness from worsening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.